, Pourquoi le cancer porte-t-il ce nom-là ?

, Institut National de Recherche et du Cancer, 2014.

, Fondation ARC pour la recherche sur le cancer. Le cancer en chiffres

D. Sur,

S. Papon, 610 000 personnes sont décédées en France en 2018, dont la moitié dans le département où elles sont nées -Insee Focus n°163

, Fédération de l'Hospitalisation Privée : Médecine, Chirurgie, Obstétrique. Les principales causes de mortalité en France [Internet]. fhpmco.fr, 2019.

D. Sur,

C. Marrant-micallef, K. D. Shield, J. Vignat, C. Hill, A. Rogel et al., Approche et méthodologie générale pour l'estimation des cancers attribuables au mode de vie et à l'environnement en France métropolitaine en, Bull Épidémiologique Hebd. 26 juin, issue.21, pp.432-474, 2015.

, Les cancers en France en 2018 -L'essentiel des faits et chiffres (édition, 2019.

, Institut National du Cancer. Données globales d'épidémiologie des cancers

. Infocancer, Le cancer en chiffres -Les taux de guérison [Internet]. arcagy.org, 2019.

C. Marrant-micallef, K. D. Shield, J. Vignat, C. Hill, A. Rogel et al., Nombre et fractions de cancers attribuables au mode de vie et à l'environnement en France métropolitaine en 2015 : résultats principaux, Bull Épidémiologique Hebd. 26 juin, issue.21, pp.442-450, 2018.

, Fondation ARC pour la recherche sur le cancer. Les facteurs de risque et la prévention [Internet]. fondation-arc.org

, Fondation ARC pour la recherche sur le cancer. Les ondes électromagnétiques [Internet]. fondation-arc.org, 2019.

M. Tubiana, . Dépistage, and . Diagnostic, Presses universitaires de France, Le cancer. 5 e éd, pp.76-94, 2003.

, Fondation pour la Recherche Médicale. Cancers : du dépistage au diagnostic, au plus tôt ! [Internet]. frm.org

, Fondation contre le Cancer. Les examens [Internet]. cancer.be

D. Sur,

, Cancer : les traitements et les soins de support, Fondation ARC pour la recherche sur le cancer

P. Mazzola, S. Radhi, L. Mirandola, G. Annoni, M. Jenkins et al., Aging, cancer, and cancer vaccines, Immun Ageing. 17 avr, vol.9, issue.4, 2012.

R. France, Pourquoi Roche s'est intéressé au système immunitaire pour lutter contre le cancer | Roche, 2017.

F. Sabatier, Réponse immunitaire anti-tumorale. Cours d'immunologie de L3 Pharmacie, 2014.

D. S. Chen and I. Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity. 25 juill, vol.39, issue.1, pp.1-10, 2013.

R. France, Qu'est-ce que le cycle de l'immunité anti-tumorale ? | Roche, 2018.

D. Sur,

L. Zitvogel, A. Tesniere, and G. Kroemer, Cancer despite immunosurveillance: immunoselection and immunosubversion, Nat Rev Immunol. oct, vol.6, issue.10, pp.715-742, 2006.

. Infocancer, Immunothérapie -Principes généraux

, Cellule cancéreuse et tissu cancéreux [Internet]. campus.cerimes.fr, Collège Français des Pathologistes (CoPath), 2011.

D. Olive, . Thi-s-le, L. Xerri, I. Hirsch, and J. A. Nunès, Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. médecine/sciences. 1 er, vol.27, pp.842-851, 2011.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer. 22 avr, vol.12, issue.4, pp.252-64, 2012.

M. Larsen, V. Appay, and D. Sauce, Influence de PD-1 sur la synapse immunologique -Une facette de la régulation immunitaire ? médecine/sciences. 1 er déc, vol.29, pp.1080-1082, 2013.

T. H. Borch, M. Donia, M. H. Andersen, and I. M. Svane, Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies, Drug Discov Today. sept, vol.20, issue.9, pp.1127-1161, 2015.

A. Franc, Le cancer féminin du poumon en hausse en France [Internet]. sante.lefigaro.fr, 2018.

D. Sur,

, Le cancer du poumon -Les cancers les plus fréquents [Internet]. e-cancer.fr, 2019.

, Cancer du poumon : points-clés [Internet]. e-cancer.fr, 2018.

, Référentiel « Carcinomes neuroendocrines bronchiques à grandes cellules

D. Sur,

. Infocancer, Epidémiologie des tumeurs de la vessie

, Types of Bladder Cancer: Common, Rare and More, Internet]. cancercenter.com, 2018.

R. France, L'essentiel sur le cancer du rein

D. Sur,

J. R. Mark, Carcinome à cellules rénales

, Édition professionnelle du Manuel MSD, 2019.

D. Sur,

, Fondation ARC pour la recherche sur le cancer. Cancers du rein : les traitements [Internet]. fondation-arc.org, 2018.

K. Bensalah, L. Albiges, J. Bernhard, P. Bigot, T. Bodin et al., Recommandations françaises du Comité de Cancérologie de l, AFU -Actualisation, vol.28, issue.12, pp.3-31, 2018.

M. Lesnik, Les cancers de la tête et du cou

C. Izzarelli, Carcinome épidermoïde et cancer de la tête et du cou

D. Sur,

, Le lymphome hodgkinien : points clés [Internet]. e-cancer.fr

. Infocancer, Les différents types de lymphomes de Hodgkin, Internet]. arcagy.org, 2018.

D. Sur,

W. B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases, Am J Med Sci. mai, vol.105, issue.5, pp.487-511, 1893.

E. D. Thomas, H. Lochte, W. C. Lu, and J. W. Ferrebee, Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy, N Engl J Med. 12 sept, vol.257, issue.11, pp.487-511, 1957.

G. Mathé, J. L. Amiel, L. Schwarzenberg, A. Cattan, and M. Schneider, Haematopoietic Chimera in Man After Allogenic (Homologous) Bone-marrow Transplantation, Br Med J. 28 déc, vol.2, issue.5373, pp.1633-1638, 1963.

W. H. Fridman, immunothérapie des cancers : véritable révolution thérapeutique. Laennec, Tome, vol.31, issue.2020, pp.20-34

, Fondation ARC pour la recherche sur le cancer. Immunothérapie : les différentes stratégies

, Immunothérapie : mode d'action, 2017.

. L'immunothérapie, , 2020.

, Prix Nobel de médecine 2018 : l'immunothérapie récompensée, 2018.

C. Vanlerberghe, Le Nobel de médecine 2018 récompense l'immunothérapie contre le cancer

. L. Sante and . Fr, , 2018.

L. Horn, D. R. Spigel, E. E. Vokes, E. Holgado, N. Ready et al., Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol. 10 déc, vol.35, issue.35, pp.3924-3957, 2017.

C. J. Langer, S. M. Gadgeel, H. Borghaei, V. A. Papadimitrakopoulou, A. Patnaik et al., Carboplatin and pemetrexed with or without pembrolizumab for advanced, nonsquamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, vol.17, issue.11, pp.1497-508, 2016.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017.

T. Y. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger et al., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol. 1 er juill, vol.17, issue.7, pp.956-65, 2016.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015.

A. V. Balar, M. D. Galsky, J. E. Rosenberg, T. Powles, D. P. Petrylak et al., Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet, vol.389, pp.67-76, 2017.

S. M. Ansell, A. M. Lesokhin, I. Borrello, A. Halwani, E. C. Scott et al., PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, N Engl J Med. 22 janv, vol.372, issue.4, pp.311-320, 2015.

J. D. Wolchok, V. Chiarion-sileni, R. Gonzalez, P. Rutkowski, J. Grob et al., Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med, vol.377, issue.14, pp.1345-56, 2017.

J. Schachter, A. Ribas, G. V. Long, A. Arance, J. Grob et al., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, vol.390, pp.1853-62, 2017.

M. Kostine, A. Marabelle, T. Schaeverbeke, and M. Kfoury, Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité. médecine/sciences. 1 er déc, vol.35, pp.949-56, 2019.

F. S. Hodi, V. Chiarion-sileni, R. Gonzalez, J. Grob, P. Rutkowski et al., Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial, Lancet Oncol. 1 er nov, vol.19, issue.11, pp.1480-92, 2018.

L. Horn, A. S. Mansfield, A. Szcz?sna, L. Havel, M. Krzakowski et al., First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med. 6 déc, vol.379, issue.23, pp.2220-2229, 2018.

C. Wang, P. Kulkarni, and R. Salgia, Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer, Mol Ther Oncolytics. 19 mars, vol.13, pp.1-6, 2019.

, Agence européenne des médicaments. YERVOY (Résumé des caractéristiques du produit, p.2020

, Agence européenne des médicaments. OPDIVO (Résumé des caractéristiques du produit, p.2020

, Agence européenne des médicaments. KEYTRUDA (Résumé des caractéristiques du produit, p.2020

K. Takada, G. Toyokawa, F. Shoji, T. Okamoto, and Y. Maehara, The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers, Clin Lung Cancer. 1 er mars, vol.19, issue.2, pp.120-129, 2018.

, Agence européenne des médicaments. LIBTAYO (Résumé des caractéristiques du produit, p.2020

, Agence européenne des médicaments, TECENTRIQ, vol.840

, Agence européenne des médicaments. TECENTRIQ 1200 mg, p.2020

, Agence européenne des médicaments. IMFINZI (Résumé des caractéristiques du produit, p.2020

S. Couraud, V. Westeel, F. Ranchon, A. Toffart, and P. Soucquet, Cancer bronchique non à petites cellules -Référentiels inter-régionaux en oncologie thoracique

, Agence européenne des médicaments. BAVENCIO (Résumé des caractéristiques du produit, p.2020

I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon et al., Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J Immunother Cancer, vol.5, issue.1, p.95, 2017.

M. S. Ernstoff, S. Gandhi, M. Pandey, I. Puzanov, P. Grivas et al., Challenges faced when identifying patients for combination immunotherapy, Future Oncol. 1 er août, vol.13, issue.18, pp.1607-1625, 2017.

J. J. Luke and P. A. Ott, PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma, Oncotarget. 28 févr, vol.6, issue.6, pp.3479-92, 2015.

P. Corbaux, D. Maillet, A. Boespflug, M. Locatelli-sanchez, M. Perier-muzet et al., Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting, Eur J Cancer, vol.121, pp.192-201, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02465794

Y. Menu, iRECIST pour (pas seulement) les nuls, J Imag Diagn Interv, vol.2, issue.2, pp.83-90, 2019.

L. Seymour, J. Bogaerts, A. Perrone, R. Ford, L. H. Schwartz et al., iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol. mars, vol.18, issue.3, pp.143-52, 2017.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline

, Eur J Cancer Oxf Engl, vol.45, issue.2, pp.228-275, 1990.

D. Schadendorf, J. D. Wolchok, F. S. Hodi, V. Chiarion-sileni, R. Gonzalez et al., Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J Clin Oncol Off J Am Soc Clin Oncol. 1 er déc, vol.35, issue.34, pp.3807-3821, 2017.

Y. Nakamura, R. Tanaka, Y. Asami, Y. Teramoto, T. Imamura et al., Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study, J Dermatol. févr, vol.44, issue.2, pp.117-139, 2017.

M. Freeman-keller, Y. Kim, H. Cronin, A. Richards, G. Gibney et al., Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes, Clin Cancer Res Off J Am Assoc Cancer Res. 15 févr, vol.22, issue.4, pp.886-94, 2016.

M. Sanlorenzo, I. Vujic, A. Daud, A. Algazi, M. Gubens et al., Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression, JAMA Dermatol, vol.151, issue.11, pp.1206-1218, 2015.

K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka et al., Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol. mars, vol.4, issue.3, 2018.

. Pawel-j-von, K. Syrigos, J. Mazieres, D. Cortinovis, R. Dziadziuszko et al., Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK, Ann Oncol. 1 er sept, vol.28, p.469, 2017.

K. C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Auclin et al., Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand, vol.1

, Blockade in Patients With Non-Small-Cell Lung Cancer, J Clin Oncol. 1 er oct, vol.36, issue.28, 2018.

B. Ricciuti, S. E. Dahlberg, A. Adeni, L. M. Sholl, M. Nishino et al., Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications, J Clin Oncol. 1 er août, vol.37, issue.22, pp.1927-1961, 2019.

S. C. Scott and N. A. Pennell, Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab, J Thorac Oncol. 1 er nov, vol.13, issue.11, pp.1771-1776, 2018.

G. Fucà, G. Galli, M. Poggi, L. Russo, G. Proto et al., Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors, ESMO Open. 27 févr, vol.4, issue.1, 2019.

A. Garant, C. Guilbault, T. Ekmekjian, Z. Greenwald, P. Murgoi et al., Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review, Crit Rev Oncol Hematol. 1 er déc, vol.120, pp.86-92, 2017.

V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews et al., Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.97-103, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02629159

G. Rossi, A. Pezzuto, C. Sini, A. Tuzi, F. Citarella et al., Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario, Crit Rev Oncol Hematol, vol.142, pp.26-34, 2019.

G. Macaigne, Effets secondaires des IPP au long cours

M. Chalabi, A. Cardona, D. Nagarkar, A. Scala, M. Albert et al., Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials, Ann Oncol. 1 er déc, vol.29, p.17, 2018.

S. Zhao, G. Gao, W. Li, X. Li, C. Zhao et al., Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer, Lung Cancer. 1 er avr, vol.130, pp.10-17, 2019.

L. Derosa, M. D. Hellmann, M. Spaziano, D. Halpenny, M. Fidelle et al., Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann Oncol. 1 er juin, vol.29, issue.6, pp.1437-1481, 2018.

J. Ahmed, A. Kumar, K. Parikh, A. Anwar, B. M. Knoll et al., Use of broadspectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors, OncoImmunology, vol.7, issue.2, 2018.

X. Mielgo-rubio, C. L. Sotelo-lezama, M. Castro, R. L. Rubio-martínez, J. Velastegui et al., Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters, J Thorac Oncol. 1 er oct, vol.13, issue.10, p.389, 2018.

M. P. Francino, Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances, Front Microbiol. 12 janv, vol.6, 2016.

D. J. Pinato, S. Howlett, D. Ottaviani, H. Urus, A. Patel et al., Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice, J Clin Oncol. 10 mars, vol.37, pp.147-147, 2019.

M. Bersanelli, D. Giannarelli, P. Castrignanò, G. Fornarini, S. Panni et al., INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study, Immunotherapy, vol.10, issue.14, pp.1229-1268, 2018.

H. Läubli, C. Balmelli, L. Kaufmann, M. Stanczak, M. Syedbasha et al., Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events, J Immunother Cancer. 1 er déc, vol.6, issue.1, p.40, 2018.

P. O. Lang, S. Govind, R. Aspinall, and . L'immunosénescence, NPG Neurol -Psychiatr -Gériatrie. août, vol.12, issue.70, pp.171-81, 2012.

D. B. Palmer, The Effect of Age on Thymic Function. Front Immunol, vol.4, 2013.

G. Pawelec, E. Derhovanessian, and A. Larbi, Immunosenescence and cancer, J Geriatr Oncol. 1 er juin, vol.1, issue.1, pp.20-26, 2010.

A. Daste, C. Domblides, M. Gross-goupil, C. Chakiba, A. Quivy et al., Immune checkpoint inhibitors and elderly people: A review, Eur J Cancer. 1 er sept, vol.82, pp.155-66, 2017.

R. Elias, A. Giobbie-hurder, N. J. Mccleary, P. Ott, F. S. Hodi et al., Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis, J Immunother Cancer. 1 er déc, vol.6, issue.1, p.26, 2018.

C. H. Kugel, S. M. Douglass, M. R. Webster, A. Kaur, Q. Liu et al., Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, Clin Cancer Res Off J Am Assoc Cancer Res. 1 er nov, vol.24, issue.21, pp.5347-56, 2018.

L. Ridolfi, D. Rosa, F. Petracci, E. Tanda, E. T. Marra et al., Anti-PD1 antibodies in patients aged ? 75 years with metastatic melanoma: A retrospective multicentre study, J Geriatr Oncol. avr, vol.11, issue.3, pp.515-537, 2020.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N Engl J Med. 11 janv, vol.378, issue.2, pp.158-68, 2018.

C. Boutros, A. Tarhini, E. Routier, O. Lambotte, F. L. Ladurie et al., Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol. 4 août, vol.13, issue.8, pp.473-86, 2016.

J. R. Brahmer, C. Lacchetti, B. J. Schneider, M. B. Atkins, K. J. Brassil et al., Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy, J Clin Oncol. 10 juin, vol.36, issue.17, pp.1714-68, 2018.

J. B. Haanen, .. G. Carbonnel, F. Robert, C. Kerr, K. M. Peters et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.29, issue.4, pp.264-270, 2018.

F. Martins, L. Sofiya, G. P. Sykiotis, F. Lamine, M. Maillard et al., Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance, Nat Rev Clin Oncol. sept, vol.16, issue.9, pp.563-80, 2019.

U. S. , Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 [Internet, 2017.

E. D. Kwon, C. G. Drake, H. I. Scher, K. Fizazi, A. Bossi et al., Ipilimumab versus placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Lancet Oncol. juin, vol.15, issue.7, pp.700-712, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168065

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012.

S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou et al., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol. 1 er avr, vol.27, issue.4, pp.559-74, 2016.

V. Sibaud, S. Boulinguez, C. Pagès, L. Riffaud, L. Lamant et al., Toxicités dermatologiques des inhibiteurs de checkpoint immunologiques, Ann Dermatol Vénéréologie. mai, vol.145, issue.5, pp.313-343, 2018.

M. Collins, J. M. Michot, F. X. Danlos, C. Mussini, E. Soularue et al., Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies, Ann Oncol, vol.28, issue.11, pp.2860-2865, 2017.

F. Carbonnel, Toxicité gastro intestinale des immunothérapies du cancer. POST'U, 2018.

S. M. Ferrari, P. Fallahi, F. Galetta, E. Citi, S. Benvenga et al., Thyroid disorders induced by checkpoint inhibitors, Rev Endocr Metab Disord. 21 sept, vol.19, issue.4, pp.325-358, 2018.

A. Faje, K. Reynolds, L. Zubiri, D. Lawrence, J. V. Cohen et al., Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis, Eur J Endocrinol. 1 er sept, vol.181, issue.3, pp.211-220, 2019.

M. Sznol, M. A. Postow, M. J. Davies, A. C. Pavlick, E. R. Plimack et al., Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat Rev. 1 er juill, vol.58, pp.70-76, 2017.

J. Naidoo, X. Wang, K. M. Woo, T. Iyriboz, D. Halpenny et al., Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy, J Clin Oncol. 1 er mars, vol.35, issue.7, pp.709-726, 2017.

E. De-martin, J. Michot, B. Papouin, S. Champiat, C. Mateus et al., Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors, J Hepatol. 1 er juin, vol.68, issue.6, pp.1181-90, 2018.

J. George, D. Bajaj, K. Sankaramangalam, J. W. Yoo, N. S. Joshi et al., Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis, Pancreatology. juin, vol.19, issue.4, pp.587-94, 2019.

M. Espi, C. Teuma, G. Basse, M. Nouvier, D. Maillet et al., Toxicité rénale des immunothérapies : résultats préliminaires de l'étude ImmuNoTox, Néphrologie Thérapeutique. sept, vol.14, issue.5, p.248, 2018.

R. Koda, H. Watanabe, M. Tsuchida, N. Iino, K. Suzuki et al., Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report, BMC Nephrol. 27 févr, vol.19, issue.1, p.48, 2018.

S. Gupta, F. B. Cortazar, L. V. Riella, and D. E. Leaf, Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, vol.27, pp.130-170

K. Sato, T. Mano, A. Iwata, and T. Toda, Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database, J Neurooncol, vol.145, issue.1, pp.1-9, 2019.

J. J. Moslehi, J. Salem, J. A. Sosman, B. Lebrun-vignes, and J. Db, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet, vol.10, p.933, 2018.

G. Varricchi, G. Marone, V. Mercurio, M. R. Galdiero, *. Tocchetti et al., Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue, Curr Med Chem, vol.31, issue.11, pp.1327-1366, 2018.

B. Baban, J. Y. Liu, X. Qin, N. L. Weintraub, and M. S. Mozaffari, Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153, PLOS ONE. 22 avr, vol.10, issue.4, p.124059, 2015.

N. Delanoy, J. Michot, T. Comont, N. Kramkimel, J. Lazarovici et al., Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study, Lancet Haematol. 1 er janv, vol.6, issue.1, pp.48-57, 2019.

K. Bitton, J. Michot, E. Barreau, O. Lambotte, O. Haigh et al., Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1

, Anticancer Immunotherapy, Am J Ophthalmol. 1 er juin, vol.202, pp.109-126, 2019.

M. E. Suarez-almazor, S. T. Kim, A. , N. Diab, and A. , Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer, Arthritis Rheumatol, vol.69, issue.4, pp.687-99, 2017.

A. M. Kumfer, Ann Marie Kumfer sur Twitter

. Twitter, , 2020.

D. Sur,

M. Donia, M. Pedersen, and I. M. Svane, Cancer immunotherapy in patients with preexisting autoimmune disorders, Semin Immunopathol. 1 er avr, vol.39, issue.3, pp.333-340, 2017.

A. Tison, G. Quéré, L. Misery, E. Funck-brentano, F. Danlos et al., Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol, vol.71, pp.2100-2111, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02267195

F. Sabatier, Aspects immunologiques et cliniques des transplantations d'organes. Cours d'immunologie de L3 Pharmacie, 2014.

K. Tanaka, M. J. Albin, X. Yuan, K. Yamaura, A. Habicht et al., PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection, J Immunol Baltim Md, vol.179, issue.8, pp.5204-5214, 1950.

E. J. Lipson, S. M. Bagnasco, J. J. Moore, S. Jang, M. J. Patel et al., Tumor Regression and Allograft Rejection after Administration of Anti-PD-1, N Engl J Med. 3 mars, vol.374, issue.9, pp.896-904, 2016.

A. Safa, H. Abudayyeh, A. Johnson, D. H. Trinh, V. A. Zobniw et al., Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature, J Immunother Cancer. 1 er déc, vol.7, issue.1, p.106, 2019.

J. Naidoo, J. Zhang, E. J. Lipson, P. M. Forde, K. Suresh et al., A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events, J Natl Compr Canc Netw. 1 er juin, vol.17, issue.6, pp.712-732, 2019.

A. Gupta, K. Felice, E. V. Loftus, and S. Khanna, Systematic review: colitis associated with anti-CTLA-4 therapy, Aliment Pharmacol Ther, vol.42, issue.4, pp.406-423, 2015.

M. A. Postow, Managing Immune Checkpoint-Blocking Antibody Side Effects, Am Soc Clin Oncol Educ Book. 1 er mai, issue.35, pp.76-83, 2015.

V. Bianchi, S. El-anbassi, and . Médicaments, , vol.1, 2019.

Y. Wang, D. H. Wiesnoski, B. A. Helmink, V. Gopalakrishnan, K. Choi et al., Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis, Nat Med, vol.24, issue.12, pp.1804-1812, 2018.

J. Haanen, K. Jordan, L. Francesca, J. Douillard, S. Jezdic et al., Guide pour les patients ESMO : Les effets secondaires liés à l'immunothérapie, 2017.

V. Bergqvist, E. Hertervig, P. Gedeon, M. Kopljar, H. Griph et al., Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis, Cancer Immunol Immunother. juin, vol.66, issue.5, pp.581-92, 2017.

C. R. Stroud, A. Hegde, C. Cherry, A. R. Naqash, N. Sharma et al., Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade, J Oncol Pharm Pract. avr, 2019.

, Site internet de la FITC -Éducation thérapeutique

. Fitcancer and . Fr,

, Consensus et recommandations de la SFE -Effets secondaires endocriniens des nouvelles thérapies anti-cancéreuses, 2018.

D. Sur,

V. Tolsma, Les infections sur cathéters : diagnostic et prise en charge, 2019.

G. Disponible,

G. Redelman-sidi, O. Michielin, C. Cervera, C. Ribi, J. M. Aguado et al., ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors), Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 1 er juin, vol.24, issue.2, pp.95-107, 2018.

H. Autorité-de-santé, Initiative des High 5s -Medication Reconciliation. Rapport d'expérimentation sur la mise en oeuvre de la conciliation des traitements médicamenteux par neuf établissements de santé français

B. Zhao, H. Zhao, and J. Zhao, Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials, Ther Adv Med Oncol, vol.16, issue.2020

E. J. Alguilar, J. Gainor, S. Kravets, S. Khosrowjerdi, C. Lydon et al., 05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%, J Thorac Oncol. 1 er oct, vol.13, issue.10, pp.367-375, 2018.

M. Coureau, A. Meert, T. Berghmans, and B. Grigoriu, Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders, Front Med, vol.7, issue.2020

A. M. Hopkins, A. Rowland, G. Kichenadasse, M. D. Wiese, H. Gurney et al., Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br J Cancer. 26 sept, vol.117, issue.7, pp.913-933, 2017.

C. Ménétrier-caux, I. Ray-coquard, J. Blay, and C. Caux, Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?, J Immunother Cancer. 28 mars, vol.7, issue.1, p.85, 2019.

A. Diehl, M. Yarchoan, A. Hopkins, E. Jaffee, and S. A. Grossman, Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors, Oncotarget. 14 déc, vol.8, issue.69, pp.114268-80, 2017.

J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. 1 er févr, vol.54, pp.139-187, 2016.

A. Sukari, M. Nagasaka, R. Alhasan, D. Patel, A. Wozniak et al., Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution, Anticancer Res. 1 er févr, vol.39, issue.2, pp.781-90, 2019.